Given the causal link we established between fibronectin secretion from myofibroblasts and perivascular amyloid accumulation, we next tested whether TGF-β inhibition could reduce both vascular fibrosis and amyloid burden. This evidence concerns the gene TGFB1 and amyloidosis.